Brief: Botanix Pharmaceuticals Appoints Howie Mckibbon As CEO
25/08/2023 02:42
Aug 25 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* APPOINTMENT OF HOWIE MCKIBBON AS CEO
* FDA APPROVAL OF SOFPIRONIUM BROMIDE IS TARGETED FOR END OF
SEPTEMBER 2023
Source text for Eikon: ID:nASX855m9W
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million